Summary

For the first time in a human trial, a class of drugs known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, already known for their weight-loss and glucose-lowering benefits, has also been shown to reduce inflammatory cells in the blood known to cause cardiovascular disease. The findings were published in Circulation.

AI summaries can be wrong sometimes—always verify important details using the source article.